10 Oct FDA Warns Florida Company: CBD is Not to be Labeled as a Dietary Supplement
The US Food & Drug Administration (FDA) is still sending out letters to CBD companies that are deemed noncompliant with existing regulations for selling CBD. Case in point, warning letter was issued to Alternative Laboratories, a dietary supplement manufacturer based in Naples, Florida.
According to the letter, the FDA conducted an inspection of the adequacy of labels for products manufactured and distributed by the company.
The letter calls attention to Alternative’s allegedly miss labeled representation of 2-amino-5 methylheptane and Octodrine (DMHA) as a dietary ingredient in certain products. The FDA concluded “that CBD products are excluded from the dietary supplement definition under” the FD&C Act.
The fact that letters are coming out of the FDA shows a need for regulation in the CBD market. As the market grows this need for regulation continues to grow as well.